Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Ewing's sarcoma and related subtypes of primitive neuroectodermal tumours share a recurrent and specific t(11;22) (q24;q12) chromosome translocation, the breakpoints of which have recently been cloned. Phylogenetically conserved restriction fragments in the vicinity of EWSR1 and EWSR2, the genomic regions where the breakpoints of chromosome 22 and chromosome 11 are, respectively, have allowed identification of transcribed sequences from these regions and has indicated that a hybrid transcript might be generated by the translocation. Here we use these fragments to screen human complementary DNA libraries to show that the translocation alters the open reading frame of an expressed gene on chromosome 22 gene by substituting a sequence encoding a putative RNA-binding domain for that of the DNA-binding domain of the human homologue of murine Fli-1.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ewing’s sarcoma, a common pediatric cancer, is invariably associated with ETS gene translocations (182) that result in a fusion oncogene consisting of the 5′ end of EWS and the 3′ end of FLI1, or less frequently ERG, ETV1, ETV4, or FEV (Figure 1a) (183, 184).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [183]
Citations
Cites
Kozak, M. (1986) · Cell · doi:10.1016/0092-8674(86)90762-2 · Cited by 4,741
Transcriptional Regulation in Mammalian Cells by Sequence-Specific DNA Binding Proteins
Mitchell, P. J., & Tjian, R. (1989) · Science · doi:10.1126/science.2667136 · Cited by 3,114
RNA recognition: towards identifying determinants of specificity
Kenan, D. J., Query, C. C., & Keene, J. D. (1991) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(91)90088-d · Cited by 730
RNA-binding proteins as developmental regulators.
Bandziulis, R. J., Swanson, M. S., & Dreyfuss, G. (1989) · Genes & Development · doi:10.1101/gad.3.4.431 · Cited by 644
Turc-Carel, C., Aurias, A., Mugneret, F., Lizard, S., Sidaner, I., Volk, C., Thiery, J. P., Olschwang, S., Philip, I., Berger, M. P., et al. (1988) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(88)90285-3 · Cited by 466
Self-citationBen-David, Y., Giddens, E. B., Letwin, K., & Bernstein, A. (1991) · Genes & Development · doi:10.1101/gad.5.6.908 · Cited by 403
Chromosome Translocation in Peripheral Neuroepithelioma
Whang-Peng, J., Triche, T. J., Knutsen, T., Miser, J., Douglass, E. C., & Israel, M. A. (1984) · New England Journal of Medicine · doi:10.1056/nejm198408303110907 · Cited by 399
Chromosomal Translocations in Ewing's Sarcoma
(1983) · New England Journal of Medicine · doi:10.1056/nejm198308253090817 · Cited by 330
Corden, J. L. (1990) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(90)90236-5 · Cited by 327
Turc-Carel, C., Philip, I., Berger, M.-P., Philip, T., & Lenoir, G. M. (1984) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(84)90002-5 · Cited by 291
Research works printed but not linked: 8
- Aurias, A., Rimbaut, C., Buffe, C., Dubousset, J. & Mazabraud, A. N. Engl. J. Med. 309, 496–497 (1983).
- Turc-Carel, C., Philip, I., Berge, R. M. P., Philip, T. & Lenoir, G. M. N. Engl. J. Med. 309, 497–498 (1983).
- De Chadarevian, J. P., Vekemans, M. & Seemayer, T. A. N. Engl. J. Med. 311, 1702–1703 (1984).
- Cavazzana, A. O. et al. Adv. Neuroblastoma Res. 2, 463–473 (1988).
- Zucman, J. et al. Genes Chrom. Cancer (in the press).
- Douglass, E. C., Valentine, M., Green, A. A., Hayes, F. A. & Thompson, E. I. J. natn. Cancer Inst. 77, 1211–1213 (1986).
- Watson, D. K., Ascione, R. & Papas, T. S. Crit. Rev. Oncogenesis 1, 409–436 (1990).
- Rouleau, G. A. et al. Am. J. hum. Genet. 46, 323–328 (1990).
Cited by
Items 701–800 of 1,002
Regulatory mechanisms of the cAMP-responsive element binding protein 3 (CREB3) family in cancers
Yuxiong, W., Li, F., Bin, L., Zhang, Y., Li, Y., Li, Y., Yishu, W., & Honglan, Z. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115335 · Cited by 41
FOXM1 Is an Oncogenic Mediator in Ewing Sarcoma
Christensen, L., Joo, J., Lee, S. B., Wai, D., Triche, T. J., & May, W. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054556 · Cited by 42
Cutaneous Neoplasms Showing EWSR1 Rearrangement
Boland, J. M., & Folpe, A. L. (2013) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31828625bf · Cited by 39
One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma
Flores, G., & Grohar, P. J. (2021) · Journal of bone oncology · doi:10.1016/j.jbo.2021.100404 · Cited by 42
ETS factors in prostate cancer
Qian, C., Li, D., & Chen, Y. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.01.009 · Cited by 46
Molecular Diagnosis of Ewing Family Tumors
Barr, F. G., & Womer, R. B. (2007) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2007.070080 · Cited by 39
Identification of target genes for EWS/ATF-1 chimeric transcription factor
Jishage, M., Fujino, T., Yamazaki, Y., Kuroda, H., & Nakamura, T. (2003) · Oncogene · doi:10.1038/sj.onc.1206074 · Cited by 40
Bernaciak, J., Szczałuba, K., Derwińska, K., Wiśniowiecka‐Kowalnik, B., Bocian, E., Sasiadek, M. M., Makowska, I., Stankiewicz, P., & Śmigiel, R. S. (2008) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.32490 · Cited by 40
“The FLI1 proto-oncogene is a member of the ETS family of transcription factors, activation of which leads to Ewing sarcoma in humans [Delattre et al., 1992].”
BackgroundMangham, D. C., Williams, A., McMullan, D., McClure, J., Sumathi, V. P., Grimer, R. J., & Davies, A. M. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02318.x · Cited by 41
Comparison of Soft Tissue Ewing's Sarcoma and Peripheral Neuroectodermal Tumor
Siebenrock, K. A., Nascimento, A. G., & Rock, M. G. (1996) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-199608000-00036 · Cited by 39
Pellı́n, A., Boix, J., Blesa, J. R., Noguera, R., Cardá, C., & Llombart‐Bosch, A. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90300-x · Cited by 39
The Prognostic and Therapeutic Relevance of p27kip1 in Ewing’s Family Tumors
Matsunobu, T., Tanaka, K., Matsumoto, Y., Nakatani, F., Sakimura, R., Hanada, M., Li, X., Oda, Y., Naruse, I., Hoshino, H., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0788-3 · Cited by 42
“As a result of this translocation, the EWS gene on chromosome 11 fuses to the Fli1 gene, a member of the ETS family of transcription factors, on chromosome 22, which generates the EWS-Fli1 chimeric gene (4).”
BackgroundSánchez‐Prieto, R., de Álava, E., Palomino, T., Viniegra, J. G., Fernandez, V., Cebrian, S., LLeonart, M. E., Cabello, P., Martín, P., Roman, C. S., et al. (1999) · Nature Medicine · doi:10.1038/12516 · Cited by 46
Molecular Prognostication for Soft Tissue Sarcomas: Are We Ready Yet?
Oliveira, A. M., & Fletcher, C. D. �. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.025 · Cited by 39
Fli-1 expression in malignant melanoma.
Torlakovic, E., Slipicevic, A., Flørenes, V. A., Chibbar, R., DeCoteau, J. F., & Bilalović, N. (2008) · PubMed · doi:10.14670/hh-23.1309 · Cited by 44
“…a putative RNA-binding domain of the Ewing sarcoma gene on chromosome 22 for the DNA-binding domain of the FLI1 gene on chromosome 11, which produces a chimeric transcription factor that requires the DNAbinding domain encoded by FLI1 for transformation (Delattre et al., 1992; May et al., 1993).”
BackgroundThe First European Interdisciplinary Ewing Sarcoma Research Summit
Kovar, H., Alonso, J., Åman, P., Aryee, D. N. T., Ban, J., Burchill, S. A., Burdach, S. E. G., de Álava, E., Delattre, O., Dirksen, U., et al. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00054 · Cited by 38
“The major driver of ES, the EWS-FLI1 gene fusion, was discovered exactly 20 years ago (Delattre et al., 1992), and there is ample experimental evidence that inhibition of EWS-FLI1 interferes with tumor growth.”
BackgroundSelf-citationCatalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy
Romo‐Morales, A., Aładowicz, E., Blagg, J., Gatz, S. A., & SHIPLEY, J. M. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27888 · Cited by 39
Liquid‒liquid phase separation: roles and implications in future cancer treatment
Liu, Z., Qin, Z., Liu, Y., Xia, X., He, L., Chen, N., Hu, X., & Peng, X. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.81521 · Cited by 46
Molecular Testing of Solid Tumors
Igbokwe, A., & Lopez-Terrada, D. H. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0413-rar.1 · Cited by 41
Berger, M., Dirksen, U., Braeuninger, A., Koehler, G., Juergens, H., Krumbholz, M., & Metzler, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056408 · Cited by 38
“The lower detection rate of the reciprocal FLI1-EWS fusion site is in line with results from other recurrent chromosomal translocations and is attributable to large deletions or complex rearrangements on der11 [18–20].”
ResultPahlich, S., Quero, L., Roschitzki, B., Leemann-Zakaryan, R. P., & Gehring, H. (2009) · Journal of Proteome Research · doi:10.1021/pr900235t · Cited by 44
Poleev, A., Hartmann, A. M., & Stamm, S. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01431.x · Cited by 40
“EWS, an RNA-binding protein [43] that interacts in the two-hybrid assay with CUG-BP, also copurifies with another RNA-binding protein and protein kinase C substrate, TLS/FUS [44] as well as with the splicing factor PSF [45].”
BackgroundMolecular cytogenetic analysis of the bladder carcinoma cell line BK-10 by spectral karyotyping
Padilla‐Nash, H. M., Nash, W. G., Padilla, G. M., Roberson, K. M., Robertson, C. N., Macville, M. V. E., Schr�ck, E., & Ried, T. (1999) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199905)25:1<6::aid-gcc2>3.0.co;2-m · Cited by 38
The RNA helicase A in malignant transformation
Fidaleo, M., Paola, E. D., & Paronetto, M. P. (2016) · Oncotarget · doi:10.18632/oncotarget.7377 · Cited by 37
“It results from the fusion between the Ewing sarcoma breakpoint region 1 gene (EWSR1) on chromosome 22 and the Friend leukemia virus integration site 1 gene (FLI1) on chromosome 11 [87].”
BackgroundCircadian control of stress granules by oscillating EIF2α
Wang, R., Jiang, X., Bao, P., Qin, M., & Xu, J. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1471-y · Cited by 40
Primary Intradural Extraosseous Ewing Sarcoma of the Spine: Case Report and Literature Review
Karikari, I. O., Mehta, A. I., Nimjee, S. M., Hodges, T. R., Tibaleka, J., Montgomery, C., Simpson, L., Cummings, T. J., & Bagley, C. A. (2011) · Neurosurgery · doi:10.1227/neu.0b013e318223b7c7 · Cited by 37
“It is thought that a transcription activation domain provided by EWS and a DNAbinding domain by FLI results in an aberrant transcription factor with oncogenic properties.(25-27) A similar mechanism of oncogenesis is thought to occur in Ewing sarcomas with translocations other than the t(11;22)(q24;q12) abnormality.”
BackgroundSampson, V. B., Kamara, D., & Kolb, E. A. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.817988 · Cited by 39
“ES was the first sarcoma to be defined by a specific translocation [44].”
BackgroundRNA splicing mediated by YB‐1 is inhibited by TLS/CHOP in human myxoid liposarcoma cells
Rapp, T. B., Yang, L., Conrad, E. U., Mandahl, N., & Chansky, H. A. (2002) · Journal of Orthopaedic Research® · doi:10.1016/s0736-0266(02)00006-2 · Cited by 45
TLS-CHOP and the Role of RNA-Binding Proteins in Oncogenic Transformation
Ron, D. (1997) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-60479-9_8 · Cited by 41
Suen, K. (1996) · Diagnostic Cytopathology · doi:10.1002/(sici)1097-0339(199607)15:1<84::aid-dc18>3.0.co;2-8 · Cited by 264
Genetic analysis of ETS genes in C. elegans
Hart, A. H., Reventar, R., & Bernstein, A. (2000) · Oncogene · doi:10.1038/sj.onc.1204040 · Cited by 36
“Transcriptional activation of ¯i-1 by either chromosomal translocation or proviral insertion leads to Ewings sarcoma in humans (Delattre et al., 1992) and erythroleukaemia in mice, respectively (Ben David et al., 1991).”
BackgroundETV6 dependency in Ewing sarcoma by antagonism of EWS-FLI1-mediated enhancer activation
Gao, Y., He, X., Wu, X., Huang, Y., Toneyan, S., Ha, T., Ipsaro, J. J., Koo, P. K., Joshua‐Tor, L., Bailey, K. M., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-022-01060-1 · Cited by 46
Oncogenic gene fusions in cancer: from biology to therapy
Liu, S. V., Nagasaka, M., Atz, J., Solca, F., & Müllauer, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02161-7 · Cited by 51
“62 The fi rst to be reported was the Philadelphia chromosome in CML in 1960.”
Oakland, T. E., Haselton, K. J., & Randall, G. C. (2013) · Journal of Virology · doi:10.1128/jvi.01006-12 · Cited by 36
Karnuth, B., Dedy, N. J., Spieker, T., Lawlor, E. R., Gattenlöhner, S., Ranft, A., Dirksen, U., Jürgens, H., & Bräuninger, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093067 · Cited by 39
“In the resulting fusion protein the transactivation domain of EWS is combined with the DNAbinding domains of FLI1 or ERG to create an aberrant transcription factor [6,7], which effects the expression of more than 1000 genes [8,9].”
MethodAnimal Models of Scleroderma: Current State and Recent Development
Asano, Y., & Sato, S. (2013) · Current Rheumatology Reports · doi:10.1007/s11926-013-0382-7 · Cited by 39
Tsuda, Y., Dickson, B. C., Swanson, D. M., Sung, Y., Zhang, L., Meyers, P. A., Healey, J. H., & Antonescu, C. R. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22828 · Cited by 38
Richter, G. H. S., Hensel, T., Schmidt, O., Saratov, V., von Heyking, K., Becker-Dettling, F. A., Prexler, C., Yen, H.-Y., Steiger, K., Fulda, S., et al. (2020) · Cancers · doi:10.3390/cancers12020304 · Cited by 37
Theisen, E. R., Selich‐Anderson, J., Miller, K. R., Tanner, J. M., Taslim, C., Pishas, K. I., Sharma, S., & Lessnick, S. L. (2020) · Epigenetics · doi:10.1080/15592294.2020.1805678 · Cited by 34
“The C-terminal FLI portion of the protein is derived from the FLI1 gene, which encodes an ETS-family transcription factor [2].”
BackgroundThe FUS::DDIT3 fusion oncoprotein inhibits BAF complex targeting and activity in myxoid liposarcoma
Zullow, H. J., Sankar, A., Ingram, D. R., Guerra, D. D. S., D’Avino, A. R., Collings, C. K., Lazcano, R., Wang, W., Liang, Y., Qi, J., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.03.019 · Cited by 41
Burdach, S. E. G., Thiel, U., Schöniger, M., Haase, R., Wawer, A., Nathrath, M., Kabisch, H., Urban, C. E., Laws, H. ‐., Dirksen, U., et al. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.184 · Cited by 36
Diagnosis and Classification of the Small Round-Cell Tumors of Childhood
Cohn, S. L. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65092-4 · Cited by 36
“The t(11;22)(q24;q12) translocation has been shown to result in the production of a chimeric gene between EWS, which codes for a novel putative RNAbinding protein, and FLI1, a member of the ETS family of transcription factors.(15) Two other variant translocations have been described that involve other members of the E…”
BackgroundPTEN Deficiency Mediates a Reciprocal Response to IGFI and mTOR Inhibition
Patel, M., Gomez, N. C., McFadden, A. W., Moats‐Staats, B. M., Wu, S. B., Muñoz-Rojas, A. R., Sapp, T., Simon, J. M., Smith, S. V., Kaiser‐Rogers, K. A., et al. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0006 · Cited by 36
“Eighty to eighty-five percent of Ewing Sarcoma tumors contain t(11;22)(q24;q12) generating an in-frame fusion of EWSR1 to FLI1 (2).”
BackgroundInfluentialLiu, T., Yao, Y., Zhang, G., Wang, Y., Deng, B., Song, J., Li, X., Han, F., Xiao, X., Yang, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14377 · Cited by 36
“This TF also undergoes translocation in most human Ewing sarcomas, generating an EWS-Fli-1 fusion protein with potent oncogenic activity [5].”
BackgroundZambelli, D., Zuntini, M., Nardi, F., Manara, M. C., Serra, M., Landuzzi, L., Lollini, P., Ferrari, S. M., Alberghini, M., Llombart‐Bosch, A., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24670 · Cited by 36
“Genetically, EWS is characterized by the presence of specific chromosomal translocations that fuse the EWSR1 gene (encoding the EWS protein) on chromosome 22 with various ETS genes.(1) The most common fusion, EWS/FLI, is present in 85% of cases, with other fusions accounting for the remaining cases.”
BackgroundSpindle cell tumors of the pleura: differential diagnosis
Rdzanek, M. A., Fresco, R., Pass, H. I., & Carbone, M. (2006) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2006.06.002 · Cited by 36
Subtracted, Unique-Sequence, In Situ Hybridization
Davison, J. M., Morgan, T. W., Hsi, B., Xiao, S., & Fletcher, J. A. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65727-6 · Cited by 36
Hou, C., Weidenbach, S., Cano, K. E., Wang, Z., Mitra, P., Ivanov, D. N., Rohr, J., & Tsodikov, O. V. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw761 · Cited by 35
“EWS–FLI1 is an abnormal fusion of parts of two proteins (EWS and FLI1), containing the DNA binding domain (DBD) of FLI1 (2,3), which is a result of a chromosomal translocation.”
BackgroundProteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue
Gierisch, M. E., Pfistner, F., Lopez-Garcia, L. A., Behrmann, L., Schäfer, B. W., & Niggli, F. K. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.752063 · Cited by 38
“Its main genetic abnormalities are EWS–ETS rearrangements, among them most commonly the EWS gene on chromosome 22 fused to FLI1 on chromosome 11 which results in expression of the chimeric transcription factor EWS-FLI1 (19-21).”
BackgroundKrystel‐Whittemore, M., Taylor, M. S., Rivera, M. N., Lennerz, J. K., Le, L. P., Dias-Santagata, D. C., Iafrate, A. J., Deshpande, V., Chebib, I. A., Nielsen, G. P., et al. (2019) · Human Pathology · doi:10.1016/j.humpath.2019.08.006 · Cited by 36
Small molecule inhibition of Ewing sarcoma cell growth via targeting the long non coding RNA HULC
Mercatelli, N., Fortini, D., Palombo, R., & Paronetto, M. P. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.026 · Cited by 37
Interplay of RNA-Binding Proteins and microRNAs in Neurodegenerative Diseases
Kinoshita, C., Kubota, N., & Aoyama, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105292 · Cited by 42
TEThered to Runx: Novel binding partners for runx factors
Li, X., Decker, M., & Westendorf, J. J. (2010) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2010.03.002 · Cited by 35
Jay, V., Zieleńska, M., Lorenzana, A., & Drake, J. M. (1996) · Pediatric Pathology & Laboratory Medicine · doi:10.1080/15513819609168668 · Cited by 39
Sozzi, G., Minoletti, F., Miozzo, M. R., Sard, L., Musso, K., Azzarelli, A., Pierotti, M. A., & Pilotti, S. (1997) · Human Pathology · doi:10.1016/s0046-8177(97)90096-4 · Cited by 35
Kikuchi, R., Murakami, M., Sobue, S., Iwasaki, T., Hagiwara, K., Takagi, A., Kojima, T., Asano, H., Suzuki, M., Banno, Y., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209973 · Cited by 35
“In EWS, chromosomal translocation produce fusion gene, EWS/Fli-1 or EWS/ERG, respectively (Delattre et al., 1992; Arvand and Denny, 2001).”
BackgroundBarrett, J. M., Puglia, M., Singh, G., & Tozer, R. G. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1014993006190 · Cited by 35
“in some acute myelogenous leukemias, Ewing’s sarcomas and primitive neuroectodermal tumours [2, 3].”
BackgroundDeAngelo, D. J., Defalco, J., Rybacki, L., & Childs, G. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.3.1254 · Cited by 38
“This interpretation is supported by the recent observation that the EWS/FLI-1 fusion protein is a more potent transcriptional activator than FLI-1 alone (34).”
BackgroundInfluentialProgress in the Molecular Biology of Ewing Tumors
Kovar, H. (1998) · Sarcoma · doi:10.1080/13577149878109 · Cited by 40
Self-citationMeyer, D., Wolff, C.-M., Stiegler, P., Sénan, F., Befort, N., Befort, J., & Rémy, P. (1993) · Mechanisms of Development · doi:10.1016/0925-4773(93)90061-2 · Cited by 35
Seroussi, E., Kedra, D., Pan, H.-Q., Peyrard, M., Schwartz, C., Scambler, P. J., Donnai, D., Roe, B. A., & Dumanski, J. P. (1999) · Genome Research · doi:10.1101/gr.9.9.803 · Cited by 40
“The gene abbreviations are as follows: (EWS) Ewing’s sarcoma gene ( Delattre et al. 1992 ); (GAR22) a gene homologous to the mouse Gas2 gene (Zucman-Rossi et al. 1996); (RRP22) a member of the Ras family of genes (Zucman-Rossi et al. 1996); (BAM22) a beta-prime adaptin gene (Peyrard et al. 1994); (ADTB1) GDB symbol; (…”
BackgroundMolecular genetics of sarcomas: Applications to diagnoses and therapy
Toguchida, J., & Nakayama, T. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01232.x · Cited by 34
Rakheja, D., Goldman, S. C., Wilson, K., Lenarsky, C., Weinthal, J., & Schultz, R. A. (2006) · Pediatric and Developmental Pathology · doi:10.2350/07-06-0296.1 · Cited by 34
Sannino, G., Marchetto, A., Ranft, A., Jabar, S., Zacherl, C., Rubío, R. A., Stein, S., Wehweck, F. S., Kıran, M. M., Hölting, T. L. B., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.002 · Cited by 34
Chemical Insights into Liquid-Liquid Phase Separation in Molecular Biology
Kamimura, Y. R., & Kanai, M. (2020) · Bulletin of the Chemical Society of Japan · doi:10.1246/bcsj.20200397 · Cited by 36
Modification of EWS/WT1 functional properties by phosphorylation
Kim, J., Lee, J. M., Branton, P. E., & Pelletier, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.25.14300 · Cited by 34
Patel, N. J., Black, J. O., Chen, X., Marcondes, A. M., Grady, W. M., Lawlor, E. R., & Borinstein, S. C. (2012) · Sarcoma · doi:10.1155/2012/498472 · Cited by 36
“The most common chromosomal translocation, present in 85% of all EWS, is t(11; 22)(q24; q12) which results in the formation of a EWSR1-FLI1 fusion gene [1].”
BackgroundThe role of FLI-1-EWS, a fusion gene reciprocal to EWS-FLI-1, in Ewing sarcoma
Elzi, D. J., Song, M., Houghton, P. J., Chen, Y., & Shiio, Y. (2015) · Genes & Cancer · doi:10.18632/genesandcancer.86 · Cited by 38
“Since the cloning of the EWS-FLI-1 fusion oncogene [6], the predominant view in the Ewing sarcoma field has been that EWS-FLI-1 plays a central role in Ewing sarcomagenesis [1-5].”
BackgroundResultZhang, Y., Wen, Z., Wan, K. M., Yuan, D., Zeng, X., Liang, G., Zhu, J., Xu, B., & Luo, H. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.153 · Cited by 35
A Novel Type of EWS-CHOP Fusion Gene in Two Cases of Myxoid Liposarcoma
Hosaka, T., Nakashima, Y., Kusuzaki, K., Murata, H., Nakayama, T., Nakamata, T., Aoyama, T., Okamoto, T., Nishijo, K., Araki, N., et al. (2002) · Journal of Molecular Diagnostics · doi:10.1016/s1525-1578(10)60698-8 · Cited by 34
The Clinical Relevance of Molecular Genetics in Soft Tissue Sarcomas
Ordóñez, J. L., Osuna, D., García-Domínguez, D. J., Amaral, A. T., Otero-Motta, A. P., Mackintosh, C., Sevillano, V., Barbado, M. V., Hernández, T., & de Álava, E. (2010) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181d98cbf · Cited by 38
Evidence for activation of KIT, PDGFRα, and PDGFRβ receptors in the Ewing sarcoma family of tumors
Bozzi, F., Tamborini, E., Negri, T., Pastore, E., Ferrari, A., Luksch, R., Casanova, M., Pierotti, M. A., Bellani, F. F., & Pilotti, S. (2007) · Cancer · doi:10.1002/cncr.22587 · Cited by 34
“9 (EWS/ERG fusion).(9) EWS/FLI 1 amplification consisted of 1 cycle at 948C for 8 minutes followed by 35 cycles at 948C for 30 seconds, then at 648C for 30 seconds and at 728C for 30 seconds, then a final cycle at 728C for 7 minutes.”
BackgroundRanganathan, S., Hill, D. A., Humphrey, P. A., Hitchcock, M. G., Dehner, L. P., & Pfeifer, J. D. (2001) · Pediatric and Developmental Pathology · doi:10.1007/s100240010141 · Cited by 34
“This fusion junction is the second most common type in PNET, and it has been designated the type II hybrid transcript [8, 32].”
BackgroundMolecular abnormalities in Ewing’s sarcoma
Burchill, S. A. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.10.1675 · Cited by 34
“Delattre O, Zucman J, Plougastel B 19 et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in tumours. Nature 359(6391), 162–165 (1992).”
BackgroundInfluentialNakamura, T., Tanaka, K., Matsunobu, T., Okada, T., Nakatani, F., Sakimura, R., Hanada, M., & Iwamoto, Y. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.4.803 · Cited by 34
Mobilization of tumour cells during biopsy in an infant with Ewing sarcoma
Zoubek, A., Kovar, H., Kronberger, M., Amann, G., Windhager, R. H., Gruber, B., & Gadner, H. (1996) · European Journal of Pediatrics · doi:10.1007/bf01955264 · Cited by 34
“EWS exon 7/FLI-1 exon 5 rearrangement, which was originally designated as type II [6].”
BackgroundSelf-citationChernova, O. B., & Cowell, J. K. (1998) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(97)00479-2 · Cited by 34
Direct transcriptional regulation of MDM2 by Fli-1
Truong, A. H. L., Cervi, D. N., Lee, J., & Ben‐David, Y. (2004) · Oncogene · doi:10.1038/sj.onc.1208323 · Cited by 36
“The clinical relevance of Fli-1 is highlighted in the pediatric disease, Ewing’s sarcoma, in which an aberrant transcription factor is created as a result of a chromosomal translocation, resulting in a fusion product between the EWS and Fli-1 genes (Delattre et al., 1992).”
BackgroundThe genomics of undifferentiated sarcoma of soft tissue: Progress, challenges and opportunities
Steele, C. D., & Pillay, N. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.009 · Cited by 33
Sánchez-Molina, S., Figuerola-Bou, E., Blanco, E., Sánchez-Jiménez, M., Táboas, P., Gómez‐González, S., Ballaré, C., García-Domínguez, D. J., Prada, E., Hontecillas‐Prieto, L., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba3058 · Cited by 33
“The EWSR1-FLI1 fusion protein, which contains the transcriptional activation and RNA binding domains of EWSR1 and the DNA binding domain of FLI1, is the main driver of tumorigenesis (3, 6).”
BackgroundEstablishment of an In Vivo Model for Pediatric Ewing Tumors by Transplantation into NOD/ scid Mice
Vormoor, J. H., Baersch, G., Decker, S., Hotfilder, M., Schäfer, K.-L., Pelken, L., Rübe, C., van Valen, F., Jürgens, H., & Dockhorn‐Dworniczak, B. (2001) · Pediatric Research · doi:10.1203/00006450-200103000-00006 · Cited by 33
“Despite this clinical heterogeneity, Ewing tumors represent a paradigm for understanding the biology of human solid tumors, as they are the first group of sarcomas for which a chromosome translocation has been characterized at the molecular level (1, 2).”
BackgroundLi, G., Ogose, A., Kawashima, H., Umezu, H., Hotta, T., Tohyama, T., Ariizumi, T., & Endo, N. (2009) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2009.02.011 · Cited by 33
Prognostic relevance of CCN3 in Ewing sarcoma
Perbal, B., Lazar, N., Zambelli, D., López‐Guerrero, J. A., Llombart‐Bosch, A., Scotlandi, K., & Picci, P. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.05.008 · Cited by 33
“Chimeric genes encoding abnormal transcription factors (FLI1, ERG, ETV1, E1AF, or FEV) are generated by these translocations [1].”
BackgroundMolecular mechanisms of OLIG2 transcription factor in brain cancer
Tsigelny, I. F., Kouznetsova, V. L., Lian, N., & Kesari, S. (2016) · Oncotarget · doi:10.18632/oncotarget.10628 · Cited by 40
Rodríguez‐Núñez, P., Romero‐Pérez, L., Amaral, A. T., Puerto‐Camacho, P., Jordán, C., Marcilla, D., Grünewald, T. G. P., Alonso, J., de Álava, E., & Díaz‐Martín, J. (2020) · The Journal of Pathology · doi:10.1002/path.5379 · Cited by 38
“EwS was the first solid malignancy defined by the presence of tumorspecific EWSR1–ETS gene fusions [4], mainly EWSR1–FLI1 translocations, which are considered the main driver of the disease, but fusion type itself does not have any impact on disease progression [5].”
BackgroundUnderstanding mesenchymal cancer: the liposarcoma-associated FUS–DDIT3 fusion gene as a model
Pérez-Mancera, P. A., & Sánchez-García, I. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.01.006 · Cited by 35
Phosphorylation of Ewing's sarcoma protein (EWS) and EWS-Fli1 in response to DNA damage
Klevernic, I. V., Morton, S., Davis, R. J., & Cohen, P. (2009) · Biochemical Journal · doi:10.1042/bj20082097 · Cited by 39
Blair, D. G., & Athanasiou, M. (2000) · Oncogene · doi:10.1038/sj.onc.1204046 · Cited by 45
“The myb-ets fusion in the E26 virus and the fusions, involving ¯i-1 and other members of the ETS family, seen in Ewing's Sarcomas (Delattre et al., 1992), and could suggest a propensity of these genes to generated oncogenic fusions.”
BackgroundEWS/FLI function varies in different cellular backgrounds
Zwerner, J. P., Guimbellot, J. S., & May, W. A. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(03)00371-9 · Cited by 35
Inhibition of G1 to S Phase Progression by a Novel Zinc Finger Protein P58TFL at P-bodies
Minagawa, K., Katayama, Y., Nishikawa, S., Yamamoto, K., Sada, A., Okamura, A., Shimoyama, M., & Matsui, T. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0511 · Cited by 33
“The universal cryptic defect of the α-type platelet-derived growth factor receptor gene (αPDGFR) in chronic eosinophilic leukemia was also first identified from a rare case with t(1;4) (q44;q12) (ref.”
BackgroundLessnick, S. L., Tos, A. P. D., Sorensen, P. H. B., Dileo, P., Baker, L. H., Ferrari, S., & Hall, K. S. (2009) · Seminars in Oncology · doi:10.1053/j.seminoncol.2009.06.006 · Cited by 35
Ichikawa, H., Shimizu, K., Katsu, R., & Ohki, M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.11.7639 · Cited by 37
“The FUS gene is highly related to the EWS gene (9).”
BackgroundLook, A. T. (1995) · Advances in cancer research · doi:10.1016/s0065-230x(08)60709-5 · Cited by 40
Molecular Genetics and Cytogenetics of Sarcomas
Kruzelock, R. P., & Hansen, M. F. (1995) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30082-0 · Cited by 37
Long way up: rethink diseases in light of phase separation and phase transition
Ding, M., Xu, W., Pei, G., & Li, P. (2023) · Protein & Cell · doi:10.1093/procel/pwad057 · Cited by 36
“Another example of tumor arises due to chromosome translocations, leading to various fusion gene products (Delattre et al., 1992; Tan and Manley, 2009) (Fig.”
BackgroundFolpe, A. L., Tetzlaff, M. T., Billings, S. D., Torres‐Mora, J., Borowsky, A. D., Santiago, T., Ameline, B., & Baumhoer, D. (2024) · Modern Pathology · doi:10.1016/j.modpat.2024.100537 · Cited by 32
Frascella, E., & Rosolen, A. (1998) · Europe PMC (PubMed Central) · Cited by 32
Molecular Pathology of Bone Tumors
Lam, S. W., van IJzendoorn, D. G. P., Cleton-Jansen, A., Szuhai, K., & Bovée, J. V. M. G. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.11.002 · Cited by 33
Fusion protein EWS-FLI1 is incorporated into a protein granule in cells
Ahmed, N. S., Harrell, L. M., Wieland, D. R., Lay, M. A., Thompson, V. F., & Schwartz, J. C. (2021) · RNA · doi:10.1261/rna.078827.121 · Cited by 34
“In 85% of Ewing sarcomas, the LC domain of EWSR1 is fused with the DBD from the FLI1, forming an oncogenic protein EWS-FLI1 (Delattre et al. 1992; Grünewald et al. 2018).”
BackgroundmRNA and protein levels of FUS, EWSR1, and TAF15 are upregulated in liposarcoma
Spitzer, J., Ugras, S. K., Runge, S., DeCarolis, P. L., Antonescu, C., Tuschl, T., & Singer, S. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20858 · Cited by 32
“Furthermore, FUS and EWSR1 are also frequent translocation partners in other sarcoma types, including Ewing’s sarcoma/ peripheral primitive neuroectodermal tumor (Delattre et al., 1992), in which EWSR1 is translocated in virtually all of the cases, desmoplastic small-round cell tumor (Ladanyi and Gerald, 1994), and lo…”
Background
Metadata
- Authors
- Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., Kovar, H., Joubert, I., de Jong, P., Rouleau, G., Aurias, A., & Thomas, G.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Venue
- Nature
- Published
- 1992-09
- Volume
- 359
- Issue
- 6391
- Pages
- 162-165
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2069351898
- Cited by
- 1,907
- References
- 30
- Citations by year
- 2026: 57 · 2025: 72 · 2024: 69 · 2023: 64 · 2022: 78 · 2021: 83 · 2020: 80 · 2019: 69 · 2018: 54 · 2017: 57 · 2016: 71 · 2015: 62 · 2014: 61 · 2013: 63 · 2012: 45
- FWCI
- 60.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- Ewing sarcoma, primitive neuroectodermal tumor, 22)(q24, EWSR1, gene fusion, chromosomal translocation, RNA-binding domain
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Chromosomes, Human, Pair 11, Chromosomes, Human, Pair 22, Cloning, Molecular, Gene Frequency, Humans, Molecular Sequence Data, Nucleic Acid Hybridization, Sarcoma, Ewing, Sequence Homology, Nucleic Acid, Transcription, Genetic, Translocation, Genetic, Restriction Mapping, DNA Probes, Polymerase Chain Reaction, Open Reading Frames, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.